Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...
Rezolute to announce DMC conclusions in April, says H.C. Wainwright
Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the ...
Rezolute Insiders Placed Bullish Bets Worth US$557.5k
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...
Hosted on MSN12h
Rezolute’s Strategic Advances in Rare Disease Therapies
Rezolute, Inc. ( ($RZLT) ) has released its Q2 earnings. Here is a breakdown of the information Rezolute, Inc. presented to its investors.
ETF Daily News3d
Guggenheim Reiterates Buy Rating for Rezolute (NASDAQ:RZLT)
Rezolute (NASDAQ:RZLT – Get Free Report) ‘s stock had its “buy” rating reaffirmed by analysts at Guggenheim in a report released on Monday,Benzinga reports.A number of other analysts have ...
JMP Securities lifts Rezolute stock target to $9, maintains rating
JMP Securities adjusted its financial outlook for Rezolute (NASDAQ:RZLT), increasing the price target to $9.00 from the previous $8.00, while keeping a Market Outperform rating on the stock. Currently ...